Lung Cancer
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression ≥ 1% (CA2241093)
- Details
ClinicalTrials.gov ID:
NCT06561386
Diagnosis Type:
NA
USOR Number:
- Address
,
P: